TG Therapeutics, Inc. (TGTX) Guidance & Earnings Results

On 2026-08-03 TG Therapeutics, Inc. raised guidance: "FY2026 BRIUMVI U.S. net product revenue target raised to $890-905M; total global revenue to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

TGTXTG Therapeutics, Inc.Follow TGTX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 8.3B
P/E TTM: 19.7
Dividend yield: —
52-week: —
Next earnings: 9 Nov, in 16 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
3 Aug 26	Raised	FY2026 BRIUMVI U.S. net product revenue target raised to $890-905M; total global revenue to ~$950M · full year
6 May 26	Raised	FY2026 BRIUMVI U.S. net product revenue target raised to $885-900 million (from $825-850 million); total global revenue target ~$925 million. · full year
26 Feb 26	Raised	FY2026 total global revenue guidance $875-900M; Q1 2026 BRIUMVI U.S. net revenue $185-190M · full year
3 Nov 25	Raised	BRIUMVI U.S. net revenue guidance raised from $570-575M to ~$585M; total global revenue from $585M to ~$600M · full year
4 Aug 25	Raised	FY2025 BRIUMVI U.S. net revenue raised to ~$570-575M from $560M; total global revenue raised to ~$585M from $575M · full year

TG Therapeutics, Inc. — questions

What guidance did TG Therapeutics, Inc. give?: On 2026-08-03: "FY2026 BRIUMVI U.S. net product revenue target raised to $890-905M; total global revenue to ~$950M"
When does TG Therapeutics, Inc. report earnings?: TG Therapeutics, Inc.'s next earnings report is expected on 2026-11-09.

Every figure on this page comes from TG Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.